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ABSTRACT
Objective: To determine whether non-pharmaceutical
retail outlets are aboding to the current Medicines and
Healthcare products Regulatory Agency (MHRA)
national guidelines for over-the-counter (OTC) sales of
aspirin and paracetamol.
Methods: Stages 1 and 2 of the study deployed eight
and four medical students, respectively, to undertake a
mystery shopper style investigation. Stage 1: eight
medical students attempted to buy ≥96 tablets/
capsules aspirin or paracetamol in one transaction in
62 shops. Stage 2: four medical students attempted to
purchase 32 paracetamol 500 mg along with a ‘flu
remedy preparation also containing paracetamol, in 54
shops.
Results: Stage 1 data revealed that 58% and 57%
retailers sold more than the MHRA guidelines
recommended for paracetamol and aspirin,
respectively. We observed that 23% and 28% retailers
were willing to sell ≥96 tablets of paracetamol or
aspirin with no questions asked. Stage 2 results
showed that 57% retailers sold 32×500 mg
paracetamol in conjunction with a paracetamol-
containing ‘flu preparation; while 98% shops sold
16×paracetamol 500 mg along with a paracetamol-
containing ‘flu remedy, with no questions asked of the
shopper or advice given.
Discussion: MHRA national guidelines for OTC
medicines sales appear to be poorly adhered to in non-
pharmacy shops. Sales of aspirin and paracetamol OTC
must be better regulated in the UK to ultimately reduce
morbidity and mortality rates of deliberate and
accidental overdoses.
INTRODUCTION
Paracetamol misuse is the number 1 cause of
overdose in the UK.1 2 Up to 90 000 presen-
tations with paracetamol overdoses are wit-
nessed in healthcare settings per year in the
UK with around 200 associated deaths that
occur annually.3–5 Deliberate overdoses are
often impulsive whereby individuals take
drugs that are already stored at home.6 7
Furthermore, many accidental overdoses
result from a person with poor pain manage-
ment, taking more than the recommended
limit from lack of education or inadvertently
exceeding the recommended dose, by taking
two or more different paracetamol-containing
preparations (eg, pure paracetamol and
Lemsip max).8
Rising overdose rates in the 1990s, led to the
UK Medicines Control Agency (now the
Medicines and Healthcare products Regulatory
Agency (MHRA)) consulting and advising the
UK government. Consequently, new legisla-
tion introduced in September 1998 resulted
in paracetamol pack size restrictions to
16×500 mg tablets/capsules/caplets at non-
pharmacy retail outlets (stores without an
in store pharmacy).9 The sale of over-the-
counter (OTC) drugs is now commonplace
with almost every newsagent, grocery and
bargain store selling them. In 2009 the
MHRA released further guidelines governing
OTC drug sales in the UK stating “no retailer
should sell more than two packets of para-
cetamol (500 mg) in one transaction, retailers
should be discouraged from promoting the
sale of more than one pack at a time and that
it is illegal to sell more than 100 tablets of
Strengths and limitations of this study
▪ All shoppers were of similar age and back-
ground, highly motivated, trained and well
briefed prior to study.
▪ Study collected quantitative data with qualitative
evidence supporting the findings.
▪ Findings will have broad implications for the
sales and safety of all over-the-counter
medications.
▪ Data collection only focused on Staffordshire and
Shropshire, however, large branded stores were
included highlighting a potential national picture.
▪ Internet sales was not explored.
Molloy P, et al. BMJ Open 2016;6:e010081. doi:10.1136/bmjopen-2015-010081 1
Open Access Research
group.bmj.com on February 18, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
paracetamol (500 mg) or aspirin (75–300 mg) in one
transaction.” 10 11 Consequently current guidelines state
that the maximum quantity recommended for OTC
sale is 32×500 mg and 32×75–300 mg for paracetamol
and aspirin, respectively, at non-pharmacy stores.
Furthermore, the law states that no more than 100
tablets/capsules/caplets (500 mg paracetamol and
7.5–30 mg aspirin) can be sold at any non-pharmacy
retail outlet or pharmacy establishment in one transac-
tion.10 Since these national guidelines were introduced
(in 2009) death rates in the UK from paracetamol over-
dose have dropped by 43%.12
However, it seems that more can be done. From pre-
liminary investigations we observed that some non-
pharmacy retail outlets were selling 48 tablets/caplets of
paracetamol (500 mg) and encouraging sale of three
packets (3×16 tablets) as bargain offers. This initiated
the initial mystery shopper exercise to explore the
extent to which a range of retailers were abiding
by MHRA guidelines in non-pharmacy retail outlets
(stage 1). These ﬁndings triggered further investigation
(stage 2). Our aim was to assess the number of stores
willing to break MHRA guidelines and the law.
METHODOLOGY
We investigated how well MHRA guidelines for limited
sales of aspirin or paracetamol were adhered to in a
range of retail outlets grouped as ‘mainstream stores’
(including Sainsbury’s, Tesco, Morrisons, Asda, Co-op,
Lidl, Aldi, Superdrug and Boots); and ‘bargain’ stores
(including Poundland, Pound World, Wilko, Savers,
Body Care, B and M, Premiere, 99p Store, Home bar-
gains, Cost cutter, Pound stretcher, and other independ-
ent stores and newsagents). We aimed to gather data
from at least 50 stores selected for their easy accessibility
for the local population, such as town centres and on
local bus routes without any exclusion criteria. Data
were collected in Spring 2015.
Stage 1
Four geographical areas across Staffordshire and
Shropshire were selected, hosting approximately 15
shops each selling paracetamol and aspirin;
Newcastle-u-Lyme and Keele, Stoke-on-Trent and
Hanley, Stafford and Stone and Shrewsbury. Sixty two
shops were selected to include as many different bargain
and other retail shops as possible (36 mainstream and
26 bargain stores). Eight medical students were
recruited and inducted as mystery shoppers and split
into four groups with one person buying aspirin and the
other paracetamol from their allocated geographical
area. They attempted to buy ≥96 tablets/capsules/
caplets (or as many as cashiers would allow in one trans-
action) and an extra item of confectionary—as typical
shoppers. Additionally, they were given a brief ‘I’m
going away for a while and suffer migraines’ to use if
questioned by cashiers.
Stage 2
Fifty-four non-pharmacy retail outlets in the same four
locations across Shropshire and Staffordshire were
selected; many similar outlets to those included in stage
1 (29 mainstream and 25 bargain stores). Four medical
students were recruited and inducted as mystery shop-
pers each tasked with purchasing two packets of para-
cetamol (16×500 mg) in conjunction with one pack of
paracetamol-containing ‘ﬂu remedy, and a bottle of
Lucozade. They were given the brief ‘My ﬂat mate has
the ‘ﬂu.’ to use if questioned.
All students performed their mystery shopping tasks
on different days, a few days apart within the same week.
Students’ time was repaid by a £30 shopping voucher
with a £50 cash payment to the shopper who purchased
the most OTC paracetamol or aspirin overall.
Where mainstream stores were included that con-
tained pharmacies (8/62 stores), mystery shoppers in
both stages only presented goods for payment at non-
pharmacy checkouts and self-service machines. Mystery
shoppers were asked in both stages to record: whether
cashiers willingly allowed transactions, if any questions
were asked, why any sale was refused, if cashiers would
accept multiple transactions of drugs to over-ride any
obstruction in payment systems, and any remarks about
sales made by cashiers. All remarks were recorded
immediately after sale of drugs through a spreadsheet
completed by mystery shoppers. Shoppers were
instructed not to attend a store more than once
and avoid effervescent preparations of paracetamol and
aspirin.
RESULTS
Data collection
Of the total 62 retail outlets selected selling paracetamol
and aspirin in the four geographical areas, eight stores
were either closed or lacked sufﬁcient stock when
mystery shoppers attempted to buy aspirin in stage 1.
Consequently data were only collected from 54 retail
outlets (32 mainstream and 22 bargain stores). Fifty-four
stores were identiﬁed from the original 62 in stage 1
which sold paracetamol and ‘ﬂu remedies, all of which
were open and contained sufﬁcient stocks to allow data
collection and inclusion in stage 2.
Paracetamol versus aspirin sales
Fifty-eight per cent (36/62) of retail outlets sold more
than the recommended quantity of paracetamol (32×
500 mg) in one transaction. Similarly, 57% (31/54) of
retail outlets sold more than the recommended quantity
of aspirin (32×300 mg). There were similar results for
aspirin and paracetamol when analysing the purchasing
of ≥96 tablets/capsules in one transaction. Twenty-three
per cent (14/62) and 28% (15/54) of stores sold ≥96
paracetamol (500 mg) and aspirin (300 mg) in one
transaction, respectively.
2 Molloy P, et al. BMJ Open 2016;6:e010081. doi:10.1136/bmjopen-2015-010081
Open Access
group.bmj.com on February 18, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
Some stores were willing to exceed sales of legal quan-
tities of aspirin and paracetamol. We observed that 5%
(3/62) and 19% (10/54) of shops were willing to sell
over 100 tablets/capsules/caplets of paracetamol and
aspirin, respectively. In the extremes we observed that a
single transaction of 240 aspirin×300 mg was sold from
an independent store, while another ‘bargain store’ sold
on two occasions in different towns, 144 paracetamol
(500 mg); and 168 aspirin (75 mg) at another store else-
where (see tables 1 and 2 and ﬁgures 1 and 2).
‘Mainstream’ versus ‘bargain’ store sales of excessive
aspirin or paracetamol
Thirty-three per cent (12/36) of the mainstream group
compared to 46% (12/26) of the bargain store group
sold >32 paracetamol (500 mg); while 19% (7/36) of
the mainstream group and 27% (7/26) of the bargain
store group sold ≥96 tablets/caplets/capsules of para-
cetamol (500 mg) in stage 1. Sales of aspirin showed
greater disparity between the two groups of stores with
38% (12/32) of cashiers in the mainstream group and
86% (19/22) in the bargain store group selling >32
aspirin (300 mg) and 16% (5/32) in the mainstream
group and 55% (10/22) in the bargain store group
selling ≥96 aspirin (300 mg).
Sales of paracetamol plus ‘flu remedies-containing
paracetamol
We found 98% (53/54) of shops included in stage 2
were willing to sell one packet of paracetamol
(16×500 mg) in conjunction with a paracetamol-
containing ‘ﬂu remedy. Furthermore, 57% (31/54) sold
two packets of paracetamol (ie, total of 32×500 mg) and
one ‘ﬂu remedy-containing paracetamol (paracetamol
content varied from 3.2 to 10 g within ‘ﬂu remedy
packets) in one transaction, thus breaking MHRA guide-
lines. When comparing mystery shop transactions for
the mainstream versus the bargain stores we found
52% (15/29) of mainstreams and 56% (14/25)
bargain stores were willing to sell two packets of para-
cetamol (total of 32×500 mg) and one ‘ﬂu remedy-
containing paracetamol.
Interesting comments from mystery shoppers in stage 1
Example 1: On attempting to purchase 96 tablets
(300 mg) of aspirin one mystery shopper was asked why
they needed so many. After they gave the scripted reply
the cashier asked if they would like anymore. As a result
the mystery shopper bought 240 tablets (15 packets of
16×300 mg aspirin) and noted that they could have
bought but had to stop the cashier supplying more. This
shop was an independent store.
Example 2: On attempting to buy 96 (500 mg) para-
cetamol from an independent newsagents the mystery
Table 1 Summary of total number of paracetamol 500 mg
tablet/capsule/caplet sales in stage 1 mystery shopping
exercise
Mystery
shops, (n) >32 ≥96
Total
pills
Average
number of
pills sold per
customer
Brand 1 1 0 1 144 144
Brand 2 3 3 2 288 96
Brand 3 1 0 1 96 96
Brand 4 1 0 1 96 96
Brand 5 1 0 1 96 96
Brand 6 1 1 0 80 80
Brand 7 5 4 2 352 70
Brand 8 5 3 2 320 64
Brand 9 2 0 1 128 64
Brand 10 4 0 1 240 60
Brand 11 3 0 1 160 53
Brand 12 1 1 0 48 48
Brand 13 5 2 0 240 48
Brand 14 4 1 1 192 48
Brand 15 7 1 1 320 46
Brand 16 1 0 0 32 32
Brand 17 3 0 0 96 32
Brand 18 3 0 0 96 32
Brand 19 1 0 0 32 32
Brand 20 2 0 0 64 32
Brand 21 1 0 0 32 32
Brand 22 1 0 0 32 32
Brand 23 1 0 0 32 32
Brand 24 4 0 0 128 32
Brand 25 1 1 0 32 32
3376 57
Table 2 Summary of total number of aspirin 75–300 mg
tablet/capsule/caplet sales in stage 1 mystery shopping
exercise
Mystery
shops, (n) >32 ≥96
Total
pills
Average
number of
pills sold per
customer
Brand 25 1 1 1 240 240
Brand 1 1 1 1 128 128
Brand 20 1 1 1 112 112
Brand 2 4 4 2 436 109
Brand 14 4 4 4 320 80
Brand 17 1 1 0 80 80
Brand 16 3 3 1 232 77
Brand 18 2 2 0 128 64
Brand 6 5 2 2 320 64
Brand 8 4 2 1 240 60
Brand 10 3 3 0 176 59
Brand 11 4 1 1 224 56
Brand 13 5 2 1 272 54
Brand 7 1 1 0 48 48
Brand 12 4 2 0 176 44
Brand 24 2 1 0 80 40
Brand 15 1 0 0 32 32
Brand 19 5 0 0 160 32
Brand 21 1 0 0 32 32
Brand 22 1 0 0 32 32
Brand 3 1 0 0 32 32
3500 70
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shopper was told that they could only purchase 32 that
day. After hearing the scripted brief, the cashier said
that they could sell them two packets (ie, 32×500 mg
paracetamol) everyday until they had enough.
Example 3: When attempting to buy seven packets
(112×500 mg paracetamol) from a mainstream store at a
self-service till, the checkout supervisor cleared the
warning message voluntarily and over-rode it with no dif-
ﬁculty; so the mystery shopper was able to purchase
112×500 mg paracetamol tablets—an illegal quantity of
paracetamol in one go with no questions asked.
Interesting comments from mystery shoppers in stage 2
Answers given when mystery shoppers were refused to
be allowed to purchase all three packets of medication
in one transaction were: ‘It’s due to guidelines’ (two
stores), ‘It’s store policy’ (three stores), ‘It’s illegal’ (one
store), ‘Someone was sacked for it recently’ (one store),
Figure 1 Average paracetamol (500 mg) purchase distribution in range of store brands included in stage 1 mystery shop. This
figure shows the average quantity of paracetamol sold at each brand store. The green line represents the current MHRA guidelines
of 32 tablets/capsules/caplets per customer in one transaction. The red line indicated the current legal threshold of 100 tablets.
Figure 2 Average aspirin (300 mg) purhcase distribution in range of store brands included in stage 1 mystery shop. This figure
shows the average quantity of aspirin sold at each brand store. The green line represents the current MHRA guidelines of 32
tables/capsules/caplets per customer in one transaction. The red line indicated the current legal threshold of 100 tablets per
customer in one transaction.
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‘I’m worried you may overdose’ (one store) and ‘I don’t
know why—I just can’t’ (15 stores). Two stores without
prompting were willing to put all three packets through
via two transactions, one cashier asked a manager who
agreed to put the products through in two transactions,
another did so after the shopper asked if it was possible,
one store told the shopper that all three packs contain
paracetamol and not to take them together. The remain-
ing 24 stores put all three products through the till with
no questions asked (see ﬁgure 3). Three mystery shop-
pers also reported that cashiers told them to go and
collect another packet of paracetamol as this was on offer
and it would save money, thus two shoppers purchased
three packets (3×16 of 500 mg) of paracetamol in con-
junction with a paracetamol-containing ‘ﬂu remedy.
Observations by mystery shoppers in stages 1 and 2
Mystery shoppers reported that most stores (41/62)
contained signs informing them that they would not
sell more than 32 tablets of paracetamol (ﬁgure 4A–F).
Mystery shoppers also noted display signs encouraging
consumers to purchase more than two packets of para-
cetamol (>2×16, 500 mg) (ﬁgure 4G,H), clearly breach-
ing current guidelines set by the MHRA. Many OTC
types of medication were placed next to everyday con-
sumables such as shampoo, deodorants etc particularly
in bargain stores. It was also observed that some stores
displayed the phrase ‘everyday value’ beneath the pro-
ducts (ﬁgure 4I).
They observed variation in ‘ﬂu remedy packaging
advice on paracetamol/other medication content: all
types of packs purchased printed a message on the front
stating the inclusion of paracetamol but the varied font
size often made it hard to distinguish the word ‘para-
cetamol’ from other ingredients listed and the product’s
brand name. Shoppers reported that a handful of stores
in the ‘mainstream’ group also contained pharmacies
(8/62); but checkout staff never referred shoppers to an
in-store pharmacist to gain professional advice for their
pain management or ‘ﬂu symptoms.
DISCUSSION
Data illustrates that regulation of OTC medication sales
across Staffordshire and Shropshire is poor with around
three of ﬁve shops breaching national guidelines and
one in four shops encroaching or breaking the legal
threshold by selling more than ≥96 tablets of either
paracetamol (500 mg) or aspirin (75–300 mg) in one
transaction. Furthermore, a total of 13 stores sold illegal
quantities of aspirin or paracetamol through selling
more than 100 tablet/capsules/caplets in one transac-
tion. There was a disparity in adherence to national
guidelines between ‘mainstream and ‘bargain’ stores.
Cashiers in bargain stores tended to breach national
guidelines that limit quantity of sales of paracetamol and
aspirin to individual customers. We also witnessed poor
regulation involving sales of paracetamol-containing ‘ﬂu
Figure 3 Comments and actions made by cashiers when purchasing aspirin and/or paracetamol in stages 1 and 2. This figure
shows the comments made to mystery shoppers by cashiers when attempting to purchase paracetamol in conjunction with
paracetamol-containing ‘flu remedies’.
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remedies in conjunction with paracetamol-only prepara-
tions, with 98% (53/54) stores selling products together
and only one acknowledging the potential dangers of
dual use. The answers and comments given by cashiers
to mystery shoppers were both alarming and interesting
and, supported our original hypothesis that lay-cashiers
appeared unaware of the national guidelines for the
sales of medicine products (ﬁgure 3) further highlight-
ing the potential dangers of OTC medication use. It is
very concerning that retail shops are selling these pre-
parations without warnings to their customers and often
in excessive quantities.
Despite many shops displaying customer information
stating the sale restrictions, a signiﬁcant proportion of
stores were breaching MHRA guidelines and the law,
seemingly unknowingly. Cashiers seemed unaware why
guidelines exist13 and so were willing to break recom-
mendations or ﬁnd loop holes for themselves or custo-
mers, such as to return to the same shop everyday to
buy the maximum amount. There was absolute disre-
gard for patient safety when an independent store was
willing to sell almost 2.5 times the legal quantity of
aspirin (240×300 mg). This attitude and commercial
behaviour cannot and should not be tolerated as it
makes overdosing with paracetamol or aspirin potentially
more likely for the general public.
Another concerning observation was the lack of public
safety and protection at self-service checkouts by the
Figure 4 Signage noted as displayed in stores by mystery shoppers in stages 1 and 2. This figure shows signs observed by
mystery shoppers in various retail stores stating the refusal of more than 32 tablets/capsules/caplets of paracetamol/ibuprofen/
aspirin (A–F). It also shows display signs advertising three packets of paracetamol/ibuprofen (G and H) and everyday value signs
underneath OTCs (I).
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absence of alerts. Some shoppers were able to buy 112
tablets/capsules/caplets paracetamol (500 mg) at main-
stream stores without any screen messages warning them
not to, or alerting self-service supervisors. Mystery shop-
pers found that until systems could be manually over-
come to not just breach guidelines but also break the
law. We therefore suggest that all stores set up arrange-
ments preventing sales of more than 32 paracetamol
(500 mg) or aspirin (300 mg) in one transaction.
Another concern was the use of ‘every day’ value signs
underneath OTC medications and their placement next
to commonly purchased consumables such as beauty
products. The psychology that these medications are
consumables rather than potentially harmful drugs is
worrying. By shops shifting medications away from these
signs and everyday products, customers may recognise
that these medications are not for everyday use and
should be used with caution. This mentality that para-
cetamol is not dangerous has been highlighted in the
media several times in recent years, with many reports
detailing how victims took multiple tablets in order to
treat pain without realising the dangers of paracetamol
overdose or other OTC drugs.14–17 There has recently
been a huge campaign to stop young people participat-
ing in the ‘#paracetamolchallenge’, whereby children
encouraged and dared one another over social media to
take multiple paracetamol before uploading images to
social media networks. This craze has hospitalised
numerous young persons with potentially life-long liver
damage.18 This again highlights wide scale public ignor-
ance of paracetamol dangers.
The 98% (53/54) of retail outlets selling 16×500 mg
paracetamol tablets/capsules in conjunction with a
paracetamol-containing ‘ﬂu preparation without any
guidance that such medications contain paracetamol was
extremely alarming. Stores should not be allowed to sell
different preparations-containing paracetamol without
adequate warning (eg, verbally informing customers that
both products contain paracetamol and should not be
taken in conjunction with one another). Pharmacists are
trained healthcare professionals who are skilled in
informing customers about potential dangers of medica-
tion and will make clinical decisions to withhold sale of
medication if they do not feel it is warranted. While we
appreciate this decision process cannot be made by lay
cashiers, the explanation that both products contain
paracetamol could be easily implemented by integrating
into till systems and staff training.
Reliance on lay advice at checkouts in stores selling
paracetamol (even when a pharmacy is elsewhere
in-store) may result in signiﬁcant harm and morbidity
which is likely avoidable with proper education of staff.
This strengthens the case to explore the beneﬁts of store
staff education concerning the potential dangers of
selling more paracetamol in one transaction, than guide-
lines permit on their health customers. It seems bizarre
that alcohol and tobacco are highly regulated and OTC
medications are not.19 We would therefore like to see
OTC medications included in the store’s training pro-
gramme for all staff. We would recommend
unannounced inspections in relation to internal or
external regulation of paracetamol and/or aspirin sales,
through the use of test purchases similar to those used
for alcohol and tobacco. The MHRA should initiate
action on stores that breach guidelines or legal limits on
paracetamol and/or aspirin sales with similar punitive
measures as those for tobacco and alcohol mis-sales.
Finally, while we appreciate we have only investigated a
small proportion of stores nationally, previous studies
elsewhere have shown similar results concerning para-
cetamol, and as our mystery shopping exercise spanned
two counties we can assume that this has provided a
good snapshot of what is happening nationally.20
This lack of automatic questioning of customers with
paracetamol in their checkout baskets, by poorly trained
staff at non-pharmacy retail outlets or checkouts does
jeopardise many customers’ safety.
Concluding remarks
Mystery shopper ﬁndings justify a much needed change
to protect consumers from careless selling of OTC medi-
cations on a wide scale across the UK, and tougher regu-
lation of stores breaching guidelines and legal limits on
the maximum quantity of paracetamol or aspirin sold in
one transaction to the same customer. Such widespread
failure of OTC regulation compromises public safety,
resulting from the apparent lack of retail store staff edu-
cation, poor fail-safe systems at checkouts and limited
information given to customers on packaging and by
sales staff.
Studies investigating the source of overdoses almost a
decade ago showed very similar results; however, there
has been insufﬁcient change in the MHRA guidelines,20
and ‘3 for 2’ bargain offers of paracetamol are simply
dangerous. The combination of poor consumer educa-
tion concerning potential dangers of excessive use of
pain relief medication, an ageing population, pressures
from an ever busier National Health Service (NHS)
system that encourages self-care, and this potential non-
adherence to national best practice guidelines will con-
tinue to underpin a high number of avoidable
paracetamol-induced deaths. If national guidelines and
regulations were enforced, so preventing the large sales
of OTC medication in one transaction, it is likely that
stockpiling of paracetamol in consumers’ homes will be
far less. Consequently, individuals are less likely to take
excessive quantities of paracetamol which is easily to
hand, in a deliberate overdose in response to a sudden
crisis. As a result, their chances of survival will be
increased, morbidity decreased with enhanced clinical
outcomes and reduced avoidable healthcare usage.
Mystery shopper ﬁndings also revealed that ingredi-
ents such as paracetamol were not generally clearly
deﬁned on the front of ‘ﬂu remedy packs. We therefore
recommend that the front covers of all packaging
contain an easy to read alert relating to paracetamol
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content, which is consistent for all brands, of sufﬁciently
a large font size that it can be read by most people
without glasses (eg, font size ≥14). We also recommend
the introduction of a nationalised logo indicating
products-containing paracetamol or aspirin to avoid acci-
dental misuse of multiple preparations (ﬁgure 5). The
logo should also be raised to provide tactile identiﬁca-
tion for blind and visually impaired people. This imple-
mentation would simplify packaging, make customers
more aware of these ingredients and be understandable
to those with poor literacy skills.
MHRA or another national oversight group might
consider setting guidelines for paracetamol content; so
rather than ‘ﬂu remedy content varying from 300 to
1000 mg paracetamol dose content be adjusted to
include the same standard quantity of paracetamol with
associated advice about the maximum ‘pure’ paraceta-
mol that can be taken within for example, 6 hours of
the paracetamol-containing ‘ﬂu remedy. Thus, pain or
temperature control management would be achieved
and individuals would have a decreased risk of overdose
through ignorance of dangers of paracetamol content in
multiple preparations.
We therefore urge the MHRA to review our recom-
mendations and industries and retailers to change their
policies and systems for example, signpost customers to
pharmacists who request substantive paracetamol or
other pain relieving medication such as codeine, utilis-
ing their knowledge especially if stores contain an
in-house pharmacy. Finally, we want to assure readers
that our recommendations have been passed onto the
MHRA and we encourage their support to drive change.
Furthermore, all retail stores included in our study have
been informed with detailed descriptions of potential
ﬂaws that we identiﬁed in their normal operating
procedures.
Limitations
Owing to the varying packet size of paracetamol/aspirin
medication and product availability especially in
some smaller stores, mystery shoppers were unable
to purchase identical amounts or types of medication
(capsules/tablets/sachets; or manufacturer). Packet quan-
tity varied from multiples of 8, 12, 16 and 20 tablets/cap-
sules/caplets/sachets. In some cases this limited
availability restricted large sales due to small quantities of
stock. Furthermore, some shoppers reported only
attempting to buy 96 tablets rather than >100 due to pack
size restrictions. Along with pack size, strength of aspirin
also varies. Many of the bargain stores sell 75 mg aspirin
as opposed to the 300 mg commonly sold in shops in the
mainstream category. However, MHRA guidelines are the
same regarding number of aspirin tablet/capsules/caplet
sales whatever the strength. Eight different people were
also used to purchase drugs in stage 1 and four others in
stage 2. All mystery shoppers were of similar ages (21–27
years); but despite their induction, they may have used
slightly different techniques and approaches to purchase
drugs. Despite using well-motivated cohorts of student
shoppers we recognise that the bonus cash incentive may
have motivated shoppers to varying degrees.
We also encountered issues when collecting data.
Eight stores were either out of stock or closed during
stage 1 aspirin data collection. Similarly, eight stores did
not stock paracetamol and paracetamol-containing ‘ﬂu
remedies when conducting the stage 2 mystery shop.
Data collection was limited to seven towns in four geo-
graphical areas around Staffordshire and Shropshire
including a small percentage of stores that were easily
accessible to the local population and would have had
aspirin, paracetamol and ‘ﬂu remedies for sale.
Finally, we did not investigate as part of our study
online purchases of OTC medications. This is an area
which has been explored and highlighted as a potential
medium to easy access of OTC medications.21
Figure 5 Proposed logos to be used for OTC medication
packaging to highlight paracetamol and aspirin ingredients.
This figure demonstrates proposed logos to include on OTC
medication products-containing aspirin (top left) and
paracetamol (top right). The logo has been incorporated onto a
product to display how we propose it could be used (bottom).
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Key recommendations
1. Establish new laws:
a. Illegal to sell >32 paracetamol at non-pharmacy counters.
b. Non-pharmacy counters not permitted to sell paracetamol
and paracetamolcontaining medications in conjunction
with one another.
2. Establish improved staff training and guidelines for sale of
paracetamol and/or aspirin.
3. Regulate OTC medication purchases internally/externally.
4. Improve all till systems to prevent >32 paracetamol tablet/
capsule sales or in conjunction with other products containing
paracetamol.
5. Remove OTC medications away from everyday value signs and
commodities.
6. Produce a standardised visual identification logo to indicate if
a product contains paracetamol or aspirin (see figure 5).
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